AKTX

Akari Therapeutics, Plc [AKTX] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

AKTX Stock Summary

Top 10 Correlated ETFs

AKTX


Top 10 Correlated Stocks

AKTX


In the News

08:00 28 Mar 2024 AKTX

Akari Therapeutics to Present at Biotech Showcase 2024

NEW YORK and BOSTON, Dec. 14, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that President and CEO Rachelle Jacques will present a company overview for in-person and virtual attendees at Biotech Showcase taking place in San Francisco, CA January 8-10, 2024, adjacent to the J.P. Morgan Healthcare Conference 2024. Akari management will attend one-on-one meetings during the conferences.

08:00 28 Mar 2024 AKTX

Akari Therapeutics to Present a Poster on Pre-Clinical Development of Long-Acting PAS-Nomacopan as a Potential Treatment for Geographic Atrophy at the 4th Annual Dry AMD Therapeutic Development Conference

BOSTON and LONDON, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Chief Scientific Officer Miles Nunn will present a poster titled Development of PASylated®-Nomacopan for Treatment of Geographic Atrophy (GA) Secondary to Dry Age-Related Macular Degeneration (dAMD) at the 4th Annual Dry AMD Therapeutic Development conference taking place November 14-16 in Boston, MA. The poster will be presented on November 15, 2023 at 3:00 pm ET.

08:00 28 Mar 2024 AKTX

Akari Therapeutics to Present at Emerging Growth Conference

BOSTON and LONDON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that the company will participate in the Emerging Growth Conference being held October 4 and 5, 2023. President and CEO Rachelle Jacques will present an overview of the company and its lead asset nomacopan, a bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), on October 4, 2023 from 11:25 am to 11:55 am ET.

11:59 28 Mar 2024 AKTX

Best Penny Stocks To Buy? 6 To Watch Before Next Week

Penny stocks hold a distinctive charm for many investors. Amidst fluctuating market trends and the occasional downturn, there's often a group of these low-cost stocks surging in value.

05:34 28 Mar 2024 AKTX

Penny Stocks To Buy? 3 To Watch While The Stock Market Is Down

There's something special about penny stocks. Even when the stock market is down, like it is today, you're likely to find at least a handful exploding higher.

08:00 28 Mar 2024 AKTX

Akari Therapeutics to Present at Biotech Showcase™ 2023

NEW YORK and LONDON, Jan. 04, 2023 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company developing advanced therapies for autoimmune and inflammatory diseases, today announced that Akari President and CEO Rachelle Jacques will present a company overview at Biotech Showcase 2023 on Monday, January 9, 2023 at 9 am ET. The presentation will include progress highlights from Akari's two priority pipeline programs: a Phase 3 clinical trial of nomacopan, a novel bispecific inhibitor of complement C5 and leukotriene B4 (LTB4), for the treatment of severe pediatric hematopoietic stem cell transplant-related thrombotic microangiopathy, and a pre-clinical program investigating long-acting PAS-nomacopan as a potential treatment for geographic atrophy.

05:58 28 Mar 2024 AKTX

Akari Therapeutics (AKTX) Stock: Why It 27.88%

The stock price of Akari Therapeutics (AKTX) fell by 27.88% in the most recent trading session. This is why.

07:00 28 Mar 2024 AKTX

Akari Therapeutics to Present Results from Compassionate Use of Nomacopan for COVID-19 (CORONET) and Identification of Clinical Deterioration Risk in COVID-19 (CASCADE) at the American Thoracic Society (ATS) 2022 Annual Meeting

NEW YORK and LONDON, May 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biotechnology company focused on developing advanced therapies for autoimmune and inflammatory diseases, today announced that two posters will be presented at the American Thoracic Society (ATS) 2022 Annual Meeting reporting results from the CORONET and CASCADE studies in patients with COVID-19 pneumonia.

07:00 28 Mar 2024 AKTX

Akari Therapeutics to Present at BIO CEO & Investor Conference

NEW YORK and LONDON, Feb. 11, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer of Akari Therapeutics, will present a company overview during the BIO CEO & Investor Conference on Tuesday, February 15, 2022 at 2:30 p.m. ET, at the New York Marriott Marquis.

07:00 28 Mar 2024 AKTX

Akari Therapeutics to Present at H.C. Wainwright BioConnect Virtual Conference

NEW YORK and LONDON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present a Company overview at the H.C. Wainwright BioConnect Conference being held virtually January 10-13, 2022.

AKTX Financial details

Company Rating
Buy
Market Cap
9.16M
Income
-6.44K
Revenue
0
Book val./share
-
Cash/share
-
Dividend
-
Dividend %
-
Employees
15
Optionable
No
Shortable
Yes
Earnings
29 Apr 2024
P/E
-26.86
Forward P/E
-0.51
PEG
-0.86
P/S
-
P/B
104.6
P/C
-
P/FCF
-0.71
Quick Ratio
1.35
Current Ratio
1.15
Debt / Equity
-
LT Debt / Equity
-
-
-
EPS (TTM)
-1.69
EPS next Y
-3.6
EPS next Q
-
EPS this Y
-73.17%
EPS next Y
113.02%
EPS next 5Y
-
EPS last 5Y
-
Revenue last 5Y
-
Revenue Q/Q
-
EPS Q/Q
-
-
-
-
-
SMA20
-
SMA50
-33.33%
SMA100
-50%
Inst Own
16.14%
Inst Trans
1%
ROA
-50%
ROE
-190%
ROC
-12.89%
Gross Margin
-
Oper. Margin
-
Profit Margin
-
Payout
-
Shs Outstand
5.06M
Shs Float
5.04M
-
-
-
-
Target Price
12000
52W Range
1.66-5.5
52W High
-63.3%
52W Low
+83.5%
RSI
32
Rel Volume
0.77
Avg Volume
8.93K
Volume
6.88K
Perf Week
-3.42%
Perf Month
-22.9%
Perf Quarter
-50.44%
Perf Half Y
-52.34%
-
-
-
-
Beta
1.028
-
-
Volatility
0.03%, 0.19%
Prev Close
-1.34%
Price
1.835
Change
-0.81%

AKTX Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-1.26-0.97-0.56-0.41-0.11
Operating cash flow per share
-1.43-0.55-0.54-0.44-0.34
Free cash flow per share
-1.43-0.55-0.54-0.44-0.34
Cash per share
0.380.260.440.220.21
Book value per share
0.850.170.390.130.03
Tangible book value per share
0.840.170.390.130.03
Share holders equity per share
0.850.170.390.130.03
Interest debt per share
-0.01000-0.09
Market cap
496.34M786.05M1.17B1.29B586.89M
Enterprise value
490.37M780.32M1.15B1.28B573.64M
P/E ratio
-24.88-36.12-66.42-73.13-84.17
Price to sales ratio
00000
POCF ratio
-22.02-64.13-68.95-68.32-27.29
PFCF ratio
-22.02-64.13-68.95-68.32-27.29
P/B Ratio
37.11204.9194.45231.81327.73
PTB ratio
37.11204.9194.45231.81327.73
EV to sales
00000
Enterprise value over EBITDA
-20.83-31.21-55.92-75.12-20.11
EV to operating cash flow
-21.76-63.66-68.13-67.83-26.68
EV to free cash flow
-21.76-63.66-68.13-67.83-26.68
Earnings yield
-0.04-0.03-0.02-0.01-0.01
Free cash flow yield
-0.05-0.02-0.01-0.01-0.04
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
0.250.230.680.550.46
Current ratio
5.331.883.371.911.15
Interest coverage
243.80004.32
Income quality
0.960.50.831.081.21
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
4.91.932.221.090.27
ROIC
-1.27-5.7-1.25-3.13-5.06
Return on tangible assets
-1.22-2.12-1-1.51-0.5
Graham Net
0.610.10.350.080.03
Working capital
13.32M4.82M12.35M5.53M1.77M
Tangible asset value
13.34M3.81M12.35M5.53M1.77M
Net current asset value
13.32M3.8M12.35M5.53M1.77M
Invested capital
00000
Average receivables
5.22M7.49M4.03M1.76M1.48M
Average payables
1.78M1.41M2.3M2.58M1.37M
Average inventory
-1M-1.52M-778.41K-260.94K-1.24M
Days sales outstanding
00000
Days payables outstanding
023.34K138.51K158.22K93.19K
Days of inventory on hand
0-19.67K-21.39K0-244.69K
Receivables turnover
00000
Payables turnover
00.02000
Inventory turnover
0-0.02-0.0200
ROE
-1.49-5.67-1.42-3.17-3.89
Capex per share
00000

Quarterly Fundamentals Overview

Last date of statement is 2023-09-30 for Q3

Metric History 2022-11-082022-12-312023-03-312023-06-30 2023-09-30
2.02K2.02K2.02K2.02K2.02K
Revenue per share
00000
Net income per share
-1.01-1.01-0.34-0.340
Operating cash flow per share
-1.15-1.15-1.09-1.090
Free cash flow per share
-1.15-1.15-1.09-1.090
Cash per share
3.883.881.631.63K0
Book value per share
0.520.520.63633.160
Tangible book value per share
0.520.520.63629.560
Share holders equity per share
0.520.520.63633.160
Interest debt per share
00000
Market cap
32.14K32.14K15.99K14.94K0
Enterprise value
18.89K18.89K8.81K-7.17M0
P/E ratio
-2.33-2.33-2.67-2.490
Price to sales ratio
00000
POCF ratio
-8.16-8.16-3.34-3.120
PFCF ratio
-8.16-8.16-3.34-3.120
P/B Ratio
17.9517.955.750.010
PTB ratio
17.9517.955.750.010
EV to sales
00000
Enterprise value over EBITDA
-3.14-3.14-1.911.56K0
EV to operating cash flow
-4.79-4.79-1.841.5K0
EV to free cash flow
-4.79-4.79-1.841.5K0
Earnings yield
-0.11-0.11-0.09-0.10
Free cash flow yield
-0.12-0.12-0.3-0.320
Debt to equity
00000
Debt to assets
00000
Net debt to EBITDA
2.22.21.561.56K0
Current ratio
1.151.151.531.530
Interest coverage
00000
Income quality
1.141.143.193.190
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
00000
Intangibles to total assets
00000
Capex to operating cash flow
00000
Capex to revenue
00000
Capex to depreciation
00000
Stock based compensation to revenue
00000
Graham number
3.453.452.2169.730
ROIC
-3.36-3.36-1.6600
Return on tangible assets
-0.25-0.25-0.1900
Graham Net
0.350.350.44443.70
Working capital
1.77K1.77K2.77K2.77M0
Tangible asset value
1.77K1.77K2.77K2.77M0
Net current asset value
1.77K1.77K2.77K2.77M0
Invested capital
00000
Average receivables
00000
Average payables
817.86K946.66988.64515.83K515.31K
Average inventory
00000
Days sales outstanding
00000
Days payables outstanding
00000
Days of inventory on hand
00000
Receivables turnover
00000
Payables turnover
00000
Inventory turnover
00000
ROE
-1.92-1.92-0.5400
Capex per share
00000

AKTX Frequently Asked Questions

What is Akari Therapeutics, Plc stock symbol ?

Akari Therapeutics, Plc is a GB stock and trading under the symbol AKTX

Is Akari Therapeutics, Plc buy or a sell ?

1 stock analysts have 1 predictions with a medium analyst target price of $12000. The lowest prediction is $12000 and the highest is $12000

What is AKTX stock prediction ?

What is Akari Therapeutics, Plc stock quote today ?

Akari Therapeutics, Plc stock price is $1.835 today.

Is Akari Therapeutics, Plc stock public?

Yes, Akari Therapeutics, Plc is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap